ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0256

Consensus Approach to a Treat to Target Strategy in Juvenile Idiopathic Arthritis Care: Report from the 2020 Pediatric Rheumatology Care and Outcomes Improvement Network Consensus Conference

Tala El Tal1, Meghan Ryan2, Brian Feldman3, Catherine Bingham4, Jon Burnham5, Michelle Batthish6, Danielle Bullock7, Kerry Ferraro8, Mileka Gilbert9, Beth Gottlieb10, Julia Harris11, Melissa Hazen12, Ronald Laxer13, Tzielan Lee14, Daniel Lovell15, Melissa Mannion16, Laura Noonan17, Edward Oberle18, Anne Paul19, Janalee Taylor20, Jennifer Weiss21, Cagri Yildirim-Toruner22 and Esi Morgan23, 1University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, 2University of Minnesota, Vadnais Heights, MN, 3The Hospital for Sick Children, Toronto, ON, Canada, 4Penn State Children's Hospital, Allentown, PA, 5Children's Hospital of Philadelphia, Philadelphia, PA, 6McMaster University, Hamilton, ON, Canada, 7University of Minnesota, Minneapolis, MN, 8Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, 9Medical University of South Carolina, Charleston, SC, 10Cohen Children's Medical Center, Lake Success, NY, 11Children's Mercy Kansas City, Overland Park, KS, 12Boston Children's Hospital, Boston, MA, 13SickKids, Toronto, ON, Canada, 14Stanford University School of Medicine, Palo Alto, CA, 15Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, 16University of Alabama at Birmingham, Birmingham, AL, 17Levine Children's Hospital/Carolinas Healthcare System, Charlotte, NC, 18Nationwide Children's Hospital, Columbus, OH, 19Cincinnati Children's Hospital Medical Centre, Cincinnati, OH, 20Cincinnati Children's Hospital, Cincinnati, OH, 21Hackensack University Medical Center, Hackensack, NJ, 22Texas Children's Hospital/Baylor College of Medicine, Houston, TX, 23Seattle Children's Hospital, Seattle, WA

Meeting: ACR Convergence 2021

Keywords: Health Care, Juvenile idiopathic arthritis, Outcome measures, Patient reported outcomes, quality improvement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Treat to target (T2T) is a strategy of adjusting treatment until a therapeutic target is reached. There is growing evidence supporting the use and efficacy of T2T in chronic rheumatic conditions. In 2018, an international task force that did not include parents or patients recommended T2T for juvenile idiopathic arthritis (JIA) treatment. After a successful pilot study, the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN), a collaborative learning health network of 21 pediatric rheumatology centers across the United States and Canada, has been working together in partnership with patients and families to implement a T2T strategy. For successful implementation in a standard and reliable way in clinical practice, agreement is needed on the following areas: key elements of both (1) target setting and (2) T2T strategy, (3) identifying barriers to implementation and (4) determining eligible patients. In response, a consensus conference was held amongst PR-COIN stakeholders centered around four questions related to the listed areas in order to understand community priorities, to include patient/parent representation, as well as to gain agreement on a statement of understanding regarding the PR-COIN approach.

Methods: PR-COIN stakeholders, including health care providers (n=16) and parents (n=4), were invited to form a voting panel. Using nominal group technique, two rounds of voting were held to address the above four areas to select the top 10 responses in rank order. Answers were recorded into an electronic polling software simultaneously by the pollsters and were viewable to the voting members. Each participant placed 7 total votes on answers they thought were of highest significance. Members were allowed to place multiple of their 7 votes on a single answer if desired. Once all votes were recorded, the pollsters revealed the top 10 items for the respective round.

Results: On October 22, 2020, a PR-COIN Consensus Conference was held. (1) Incorporation of patient goals ranked most important when setting a treatment target in both voting rounds. (2) Use of shared decision making (SDM), tracking measurable outcomes, and adjusting treatment to achieve goals were voted as top elements of T2T strategy. (3) Lack of incorporation of T2T into clinic workflow and provider participation in T2T strategy were identified as key barriers to T2T implementation. (4) Patients with JIA with poor prognostic factors and at risk for high disease burden were leading candidates for a T2T approach. Results of the second round of panel voting on the four questions are shown in Tables 1-3.

Conclusion: Thisconsensus conference identified the importance of incorporating patient goals as part of target setting and the influence of patient-stakeholder involvement in drafting treatment recommendations. The PR-COIN approach to T2T will be modified to address the above findings including solicitation of patient goals, optimizing SDM, and better workflow integration. Additional efforts will be required to optimally solicit patient goals and conduct longitudinal monitoring of progress.

Table 1: top ranked answers from second voting rounds for question 1 about key elements in target setting

Table 2: top ranked answers from second voting rounds for question 2 about key elements in Treat to Target

Table 3: top ranked answers from second voting rounds for question 3 and 4 about important barriers in implementation of Treat to Target and eligible patients


Disclosures: T. El Tal, None; M. Ryan, None; B. Feldman, Pfizer, 12, DSMB member, AB2 Bio, 12, DSMB member; C. Bingham, None; J. Burnham, None; M. Batthish, Abbvie, 5, Novartis, 6, Mylan, 1, Sobi, 1; D. Bullock, Novartis, 6; K. Ferraro, None; M. Gilbert, None; B. Gottlieb, None; J. Harris, None; M. Hazen, None; R. Laxer, None; T. Lee, None; D. Lovell, Bristol Myers Squibb, 12, PI, Abatacept, Juvenile Idiopathic Arthritis, AstraZeneca Pharm, 2, Boehringer Ingleheim, 2, GSK, 2, Hoffman LaRoche, 2, Janssen, 12, Co-PI of overall studies of IV and sub-Q Golimumab in JIA, NIH / NIAMS, 12, R01 AR074098-01A1, NIH / NICHD, 12, NIH / R01 HD 089928-01A1, Novartis, 2, Pfizer, 3, Roche, 12, PI, Tociluzumab, Juvenile Idiopathic Arthritis, UBC, 2; M. Mannion, None; L. Noonan, None; E. Oberle, None; A. Paul, None; J. Taylor, None; J. Weiss, None; C. Yildirim-Toruner, None; E. Morgan, None.

To cite this abstract in AMA style:

El Tal T, Ryan M, Feldman B, Bingham C, Burnham J, Batthish M, Bullock D, Ferraro K, Gilbert M, Gottlieb B, Harris J, Hazen M, Laxer R, Lee T, Lovell D, Mannion M, Noonan L, Oberle E, Paul A, Taylor J, Weiss J, Yildirim-Toruner C, Morgan E. Consensus Approach to a Treat to Target Strategy in Juvenile Idiopathic Arthritis Care: Report from the 2020 Pediatric Rheumatology Care and Outcomes Improvement Network Consensus Conference [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/consensus-approach-to-a-treat-to-target-strategy-in-juvenile-idiopathic-arthritis-care-report-from-the-2020-pediatric-rheumatology-care-and-outcomes-improvement-network-consensus-conference/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/consensus-approach-to-a-treat-to-target-strategy-in-juvenile-idiopathic-arthritis-care-report-from-the-2020-pediatric-rheumatology-care-and-outcomes-improvement-network-consensus-conference/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology